{
    "nct_id": "NCT03826992",
    "official_title": "A Phase I Study of Venetoclax Combined with Vyxeos (CPX-351) for Children, Adolescents and Young Adults with Relapsed or Refractory Acute Leukemia",
    "inclusion_criteria": "* Ages 1 Year to 39 Years\n* Diagnosis of one of the following:\n\n  * Acute myeloid leukemia (AML), any subtype except\n\n    * Patients with acute promyelocytic leukemia (APML) are NOT eligible\n    * Patients with ML-DS are NOT eligible\n  * Myeloid sarcoma\n  * Acute leukemia of ambiguous lineage (ALAL)\n\n    * Acute undifferentiated leukemia (AUL)\n    * T/myeloid mixed phenotype acute leukemia (MPAL)\n    * B/myeloid MPAL\n    * MPAL with KMT2A-rearrangement MPAL with t (9;22) are NOT eligible\n  * T-cell acute lymphoblastic leukemia (T ALL)\n  * Early thymocyte precursor (ETP) ALL\n  * KMT2A-rearranged ALL\n* Disease Status\n\n  * Relapsed/Refractory AML, MPA, and AUL\n  * Untreated therapy related AML\n  * Relapsed/Refractory KMT2A-rearranged ALL, T-cell ALL, ETEP ALL\n* Karnofsky/Lanksy performance level score of greater than or equal to 50 percent.\n* Prior therapy requirements\n\n  * Fully recovered from acute toxicities of Hematopoietic Stem Cell Transplant (HSCT) or Anthracycline Exposure\n  * 14 days must have elapsed since the completion of systemic cytotoxic therapy other than hydroxyurea, decitabine or azacitidine\n  * 2 weeks must have elapsed for local palliative radiotherapy (RT); 6 months must have elapsed if prior craniospinal RT or if 50% radiation of pelvis, and at least 6 weeks must have elapsed if other substantial bone marrow radiation\n* Adequate renal, liver, cardiac, and central nervous system (CNS) function\nHealthy volunteers allowed\nMust have minimum age of 1 Year\nMust have maximum age of 39 Years",
    "exclusion_criteria": "* Diagnosis of one of the following:\n\n  * Myeloid Leukemia associated with Down Syndrome (ML-DS)\n  * Acute Promyelocytic Leukemia (APML)\n  * Acute leukemia with CNS status 3 involvement\n  * Philadelphia chromosome t(9;22) positive leukemia (Ph+ ALL, AML, MPAL, or AUL)\n  * Fanconi Anemia, Shwachman-Diamond syndrome, or any other bone marrow failure syndrome or DNA repair disorder\n  * Wilson's Disease or other copper-metabolism disorder\n* Pregnant or breastfeeding\n* Uncontrolled infection\n* Received greater than 13.6 Gray (Gy) prior radiation to the mediastinum\n* Unable to swallow tablets\n* Receipt of growth factors within 7 days prior to enrollment\n* Currently receiving another investigational drug\n* Currently receiving anti-cancer agents (with the exception of intrathecal (IT) agents or hydroxyurea)\n* Unable to comply with the safety monitoring requirements of the study",
    "miscellaneous_criteria": ""
}